Pharmaceutical Material Scientists are critical to the development and optimization of materials used in drug formulation and manufacturing. They focus on understanding the chemical and physical properties of excipients, polymers, and active pharmaceutical ingredients (APIs) to ensure drug formulations are stable, bioavailable, and effective. Their role involves selecting and designing materials that improve the solubility, stability, and controlled release of drugs, addressing challenges in the delivery of both traditional small-molecule drugs and newer biologics. By tailoring materials to specific drug delivery needs, pharmaceutical material scientists help enhance the overall therapeutic outcomes while minimizing potential side effects.
Formulation scientists, regulatory bodies, and production teams rely on pharmaceutical material scientists for their expertise throughout the drug development process—from early-stage research to large-scale manufacturing. Their contributions are essential in designing innovative drug delivery systems that target specific tissues, improve patient compliance, and ensure long-term drug efficacy. With the rise of complex treatments such as gene therapies, personalized medicines, and biologics, pharmaceutical material scientists play an increasingly important role in developing next-generation drug products. Their work ensures that new therapies are not only effective but also safe, sustainable, and cost-efficient, ultimately improving patient care and driving advancements in modern medicine. By optimizing the materials used in drug development, these specialists are at the forefront of creating novel and cutting-edge drug delivery technologies.
Title : Medical liver biopsy: Toward a personalized approach
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through design-inspired biotech- & biopharma-driven applications and upgraded business marketing to secure the human healthcare and biosafety
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Mathematical modeling the disc diffusion test: Antibacterial activity of copper-doped SnO2
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Genetic keys and nano locks: Unlocking personalized medicine
Srividya Narayanan, Northeastern University, United States
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico